A fixed-dose combination tablet containing a new form of the antiretroviral agent tenofovir has gained FDA approval for treating HIV-1 infection in adults and adolescents 12 years or older.
Marketed as Genvoya, the medication contains elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. It’s taken once daily as a complete regimen and is recommended for treatment-naive patients and adults with HIV-1 RNA levels below 50 copies/mL who have taken a stable antiretroviral regimen for at least 6 months without treatment failure (http://1.usa.gov/1RYxl7t). The most common adverse event linked with the drug is nausea.
Voelker R. New Form of Tenofovir. JAMA. 2015;314(23):2497. doi:10.1001/jama.2015.16486
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: